I’m not saying there aren’t lots of very smart
Post# of 148187
Just saying that based on a recent WSJ article, this is the hottest biotech deal market ever (much higher deal Volume and number and dollars being put to work in early stage companies than back when GILD was under a buck). There are an army of analysts combing the industry we can be sure. So we must be on the radar. And the market is frothy - buyers are doing aggressive stuff to put money to work.
Yet the only deals we get are at a 130mm valuation (plus free warrants) - for what some have called the next Humira?
Maybe I’m the only one who thinks it’s odd.